{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T17:27:53Z","timestamp":1771954073042,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100013700","name":"National Comprehensive Cancer Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.clml.2020.12.020","type":"journal-article","created":{"date-parts":[[2020,12,25]],"date-time":"2020-12-25T03:46:35Z","timestamp":1608867995000},"page":"139-146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4783-2643","authenticated-orcid":false,"given":"Swetha Kambhampati","family":"Thiruvengadam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bita","family":"Fakhri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiyun Z.","family":"Ai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence D.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph M.","family":"Tuscano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew J.","family":"Wieduwilt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akshay","family":"Sudhindra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Cavallone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesika","family":"Reiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlie","family":"Aoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5637-5176","authenticated-orcid":false,"given":"Michelle","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Ta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6822-7138","authenticated-orcid":false,"given":"Diem","family":"Le","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Padilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4681-6227","authenticated-orcid":false,"given":"Charalambos B.","family":"Andreadis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.12.020_bib1","author":"Howlander"},{"key":"10.1016\/j.clml.2020.12.020_bib2","first-page":"148","article-title":"Impact of rituximab (rituxan) on the treatment of B-cell non-Hodgkin\u2019s lymphoma","volume":"35","author":"Dotan","year":"2010","journal-title":"P\u00a0T"},{"key":"10.1016\/j.clml.2020.12.020_bib3","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1634\/theoncologist.2011-0341","article-title":"Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside","volume":"17","author":"Mato","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2020.12.020_bib4","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1182\/asheducation-2011.1.498","article-title":"Relapsed\/refractory diffuse large B-cell lymphoma","volume":"2011","author":"Friedberg","year":"2011","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2020.12.020_bib5","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood-2018-03-791392","article-title":"Update on mantle cell lymphoma","volume":"132","author":"Maddocks","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.12.020_bib6","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.12.020_bib7","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1080\/10428190701472021","article-title":"Bendamustine in lymphomas: more to combine?","volume":"48","author":"Bertoni","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.12.020_bib8","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1200\/JCO.2007.12.5070","article-title":"Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin\u2019s lymphoma: results from a phase II multicenter, single-agent study","volume":"26","author":"Friedberg","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.12.020_bib9","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","article-title":"Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma","volume":"26","author":"Robinson","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.12.020_bib10","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin\u2019s lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.12.020_bib11","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.2174\/1381612811319220012","article-title":"From bortezomib to other inhibitors of the proteasome and beyond","volume":"19","author":"Buac","year":"2013","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.clml.2020.12.020_bib12","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.critrevonc.2013.02.005","article-title":"The role of the ubiquitin proteasome system in lymphoma","volume":"87","author":"Suh","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clml.2020.12.020_bib13","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.12.020_bib14","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/sj.leu.2404511","article-title":"Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma","volume":"21","author":"Weigert","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2020.12.020_bib15","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1182\/blood.V106.11.2407.2407","article-title":"Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma","volume":"106","author":"Wadehra","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.12.020_bib16","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/sj.leu.2404959","article-title":"Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in\u00a0vitro and in\u00a0vivo","volume":"22","author":"Wang","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2020.12.020_bib17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4161\/mabs.1.1.7472","article-title":"Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma","volume":"1","author":"Alinari","year":"2009","journal-title":"MAbs"},{"key":"10.1016\/j.clml.2020.12.020_bib18","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1200\/JCO.2010.32.1844","article-title":"Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study","volume":"29","author":"Fowler","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.12.020_bib19","doi-asserted-by":"crossref","first-page":"4468","DOI":"10.1158\/1078-0432.CCR-20-1345","article-title":"A\u00a0three-arm randomized phase II study of bendamustine\/rituximab with bortezomib induction or lenalidomide continuation in untreated follicular lymphoma: ECOG-ACRIN E2408","volume":"26","author":"Evens","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2020.12.020_bib20","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.2147\/CMAR.S150653","article-title":"Carfilzomib for relapsed and refractory multiple myeloma","volume":"11","author":"Groen","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.clml.2020.12.020_bib21","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","article-title":"A\u00a0phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma","volume":"120","author":"Siegel","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.12.020_bib22","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.12.020_bib23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1182\/blood-2014-03-563759","article-title":"Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study","volume":"124","author":"Bringhen","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.12.020_bib24","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2019.37.15_suppl.8002","article-title":"Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: results from the FORTE trial","volume":"37","author":"Gay","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.12.020_bib25","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2020.12.020_bib26","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/bjh.12452","article-title":"The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma","volume":"162","author":"Gu","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.12.020_bib27","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S1470-2045(18)30354-1","article-title":"Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study","volume":"19","author":"Moreau","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2020.12.020_bib28","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.12.020_bib29","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Study group indolent Lymphomas (StiL). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2020.12.020_bib30","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.12.020_bib31","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.12.020_bib32","doi-asserted-by":"crossref","first-page":"7512","DOI":"10.1200\/jco.2006.24.18_suppl.7512","article-title":"Bortezomib in relapsed or refractory mantle cell lymphoma (MCL): results of the PINNACLE study","volume":"24","author":"Goy","year":"2006","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020310417?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020310417?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T06:36:33Z","timestamp":1730529393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020310417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S2152265020310417"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.12.020","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.12.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}